In this podcast, Thomas Schinecker, the CEO of Roche, shares insights about the company's journey and its role in advancing cancer treatment. He delves into the evolution of Basel as a biopharma hub and highlights significant breakthroughs, such as understanding the genome and antibody targeting. Schinecker also discusses Roche's robust drug development pipeline and the challenges Europe faces in keeping pace with the US and China in clinical trials. Additionally, he addresses the complexities of drug pricing and offers his personal perspective on leading Roche into the future.
